Opioid Use Disorder
Cluster Number:
Wiki Number: PW144
Diagnosis: Opioid Use Disorder
US Patients: About 27 million in 2016
World Patients:
Sex Ratio: M+;F
Age Onset: Young adults
Brain Area: Opioids reduce dopamine in nucleus accumbens. Neuroimaging affects in the orbitofrontal area-reducing reward-behaviors
Symptoms: strong desire to use oioids, tolerance, withdrawal symptoms & living normal lives; most US heroin users began with prescriptions
Progression: Long term use shows dysregulation of brain circuits for emotion, distress and high impulsivity.
Causes:
Medications: opioid replacement threrapy uses methadone or buprenophine and naltrexone; heroin withdrawal symptoms from 2 days-2 weeks
Therapies: CBT; Lohr’s “Calming My Pain!” (DVD or Download from this website) helps to retrain the brain to reduce pain without opioids.
Youtube Video:Here’s Why Opioid Addiction Is So Intense
Amazon or Library Book: Decisions In Recovery:
Treatment for Opioid Use Disorder
Click the text to click or buy from Amazon.
samhsa.gov; 800-662-4357
(U.S. Substance Abuse and Mental Services Administration Help)
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Defying Conventionby Liba Blumberger on May 8, 2024
No abstract
- Levels of engagement among office-based opioid treatment (OBOT) patients with concurrent methamphetamine useby Courtney L Coules on May 7, 2024
BACKGROUND AND OBJECTIVES: Recent increases in methamphetamine use among people seeking treatment for opioid use disorder (OUD) has created significant demand for effective approaches to support this clinical population. This study assessed the extent to which office-based opioid treatment (OBOT) patients, who were diagnosed with methamphetamine use disorder (MUD), engaged with providers.
- Prevalence and predictors of medication for opioid use disorder among reproductive-aged womenby Jennifer K Bello on May 7, 2024
CONCLUSIONS: We identified a significant unmet need among both pregnant and non-pregnant women with OUD seeking care in publicly funded treatment clinics. While women who are pregnant are significantly more likely to receive evidence-based treatment with MOUD, still 47.21% of pregnant women did not receive MOUD. All reproductive-aged women with OUD should be offered evidence-based treatment options, including MOUD.
- Transcriptomic characterization of human lateral septum neurons reveals conserved and divergent marker genes across speciesby Robert A Phillips on May 7, 2024
The lateral septum (LS) is a midline, subcortical structure, which regulates social behaviors that are frequently impaired in neurodevelopmental disorders including schizophrenia and autism spectrum disorder. Mouse studies have identified neuronal populations within the LS that express a variety of molecular markers, including vasopressin receptor, oxytocin receptor, and corticotropin releasing hormone receptor, that control specific facets of social behavior. Despite its critical role in the...